Biogen Idec and Swedish Orphan Biovitrum (Sobi) have announced new data from Phase III registrational studies supporting recombinant Fc fusion proteins’ ability to provide long-lasting protection from bleeding in patients with haemophilia A and B.

Investigational recombinant factors VIII Fc fusion protein (rFVIIIFc) and IX Fc fusion protein (rFIXFc) have demonstrated the ability to protect haemophilia patients from bleeding for a longer time with fewer injections than the current standard of care.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Biogen Idec haemophilia therapeutic area chief medical officer and global medical affairs senior vice president Dr Glenn Pierce said the data from the Phase III trials supports the transformation of haemophilia treatment by offering long-lasting protection from bleeding at the same time as meaningfully reducing treatment burden associated with the disease.

"Investigational recombinant factors VIII Fc fusion protein (rFVIIIFc) and IX Fc fusion protein (rFIXFc) have demonstrated the ability to protect haemophilia patients from bleeding for a longer time with fewer injections than the current standard of care."

"Less frequent injections may help more people with haemophilia adhere to a preventative treatment schedule, which can help prevent the long-term health consequences associated with treating a bleed after it occurs," Pierce said.

The pharmacokinetic activity of rFVIIIFc for haemophilia A and rFIXFc for haemophilia B were compared with the currently available treatments in the studies.

See Also:

In the studies, the candidates stayed active in the body for a longer time, allowing participants to prevent bleeding with less frequent injections.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Patients with haemophilia A used once to twice-weekly prophylactic rFVIIIFc injections to maintain low bleeding rates in the A-LONG study.

In the B-LONG study, haemophilia B patients used prophylactic rFIXFc injections every one to two weeks with low bleeding rates.